SAMD13 and glioblastoma: The comparison of expression level between each type of normal and cancer cells revealed that SAMD13 increased in breast invasive carcinoma, cholangiocarcinoma, glioblastoma multiforme, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, prostate adenocarcinoma, and stomach adenocarcinoma, while decreased in colon adenocarcinoma, head and neck squamous cell carcinoma, kidney chromophobe, rectum adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma (Fig. 1A).